Actinium Pharmaceuticals, Inc. (ATNM)

Kritische 8-K Meldungen

WARNUNG: Kritische 8-K-Meldung(en)
HOCH Abgang Schlüsselpersonen (13.02.2026)

Datum	Meldung	Schwere	Filing	Auszug
13.02.2026	Item 5.02 — Abgang Schlüsselpersonen	HOCH	SEC	Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Office
27.11.2024	Item 5.02 — Abgang Schlüsselpersonen	HOCH	SEC	Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers;
05.11.2024	Item 5.02 — Abgang Schlüsselpersonen	HOCH	SEC	Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers;
01.12.2023	Item 5.02 — Abgang Schlüsselpersonen	HOCH	SEC	Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

Stammdaten

Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for BMT conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center. The company also offers clinical and preclinical development programs that utilize multiple isotopes, including Actinium-225, Iodine-131, and Lutetium-177 directed at multiple validated cancer targets, including CD45, CD33, CD38, CD47, HER2, and HER3 for targeted conditioning prior to cell and gene therapies, such as bone marrow transplant and cancer therapeutics as single agents or in combination with other therapeutic modalities. It has collaboration with Astellas Pharma, Inc. to develop theranostics for solid tumor indications; EpicentRx, Inc that focuses on a novel CD47 immunotherapy targeted radiotherapy; and AVEO Oncology that focuses on developing a HER3 targeting ARC for solid tumors. The company was incorporated in 2000 and is based in New York, New York.

Unternehmen & Branche

Name	Actinium Pharmaceuticals, Inc.
Ticker	ATNM
CIK	0001388320
Boerse	US
Sektor	Healthcare
Industrie	Biotechnology
SIC	2834 · Pharmaceutical Preparations

Wertpapier & Kennzahlen

CUSIP	–
ISIN	–
Typ	Common Stock
Marktkapitalisierung	36,7 Mio. USD
Beta	-0,21
Dividendenrendite	0,00 %

Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »

Finanzkennzahlen (SEC XBRL)

Periode	Filing	Umsatz	Nettoergebnis	EPS	Aktiva	Eigenkapital
2025-12-31	10-K	90,000	-33,887,000	-1.09	51,775,000	7,834,000
2025-09-30	10-Q	90,000	-5,131,000	-0.16	56,151,000	13,784,000
2025-06-30	10-Q		-6,878,000	-0.22	63,017,000	19,013,000
2025-03-31	10-Q		-15,938,000	-0.51	68,647,000	25,694,000
2024-12-31	10-K		-38,243,000	-1.27	76,899,000	32,758,000
2024-09-30	10-Q		-11,568,000	-0.37	82,114,000	38,208,000
2024-06-30	10-Q		-11,353,000	-0.38	89,861,000	43,835,000
2024-03-31	10-Q		-8,670,000	-0.31	88,352,000	43,857,000
2023-12-31	10-K	81,000	-48,818,000	-1.83	81,445,000	36,379,000
2023-09-30	10-Q		-13,276,000	-0.49	88,944,000	43,583,000
2023-06-30	10-Q		-15,181,000	-0.58	99,051,000	53,077,000
2023-03-31	10-Q		-11,037,000	-0.43	102,026,000	57,208,000
2022-12-31	10-K	1,030,000	-33,017,000	-1.37	114,192,000	66,481,000
2022-09-30	10-Q	45,000	-9,474,000	-0.38	116,816,000	71,255,000
2022-06-30	10-Q	45,000	-7,767,000	-0.33	121,800,000	78,181,000
2022-03-31	10-Q	940,000	-5,129,000	-0.23	74,562,000	68,837,000
2021-12-31	10-K	1,144,000	-24,774,000	-1.20	80,388,000	73,545,000
2021-09-30	10-Q	233,000	-6,423,000	-0.30	84,479,000	80,285,000
2021-06-30	10-Q	266,000	-5,021,000	-0.25	84,454,000	80,499,000
2021-03-31	10-Q	622,000	-5,320,000		75,097,000	70,736,000

Fondsaktivität (Vorquartalsvergleich)

Keine Fondsdaten für dieses Unternehmen vorhanden.

Insider-Transaktionen (12 Monate)

Keine Insider-Käufe/Verkäufe in den letzten 12 Monaten.

Top-Fondshalter

Keine Fondsdaten zu dieser Aktie vorhanden.